Furthermore, the combined measurement of CK18‐M65 and CK18‐M30 demonstrated strong discriminatory ability for identifying NAFLD patients with concurrent CHD in this study, highlighting their potential diagnostic utility as complementary biomarkers. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.